torii pharmaceutical annual report

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. About Torii Pharmaceutical Co., Ltd. The Company promotes medical products of its parent company, Japan Tobacco. WEST CHESTER, PA – Nov. 9, 2020 (GLOBE NEWSWIRE) – Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the third quarter ended September 30, 2020. 4.0199 0.1299 (3.34%) Upgrade to Real-Time Afterhours . Torii has entered into Option Agreement with Verrica Pharmaceuticals to Develop & Commercialize VP-102 in Japan(PDF) "Financial Results " was updated. General and administrative expenses were $4.6 million in the third quarter of 2020, compared to $3.5 million for the same period in 2019. In addition, we have continued to engage with Torii as they evaluate the option to exclusively license VP-102 in Japan for the treatment of molluscum contagiosum and common warts. Verrica reported a net loss of $29.7 million for the nine months ended September 30, 2020, compared to a $20.6 million net loss for the same period in 2019. JT concentrates on R&D, while Torii Pharmaceutical Co., Ltd. is in charge of manufacturing, sales, and promotion in the Japanese domestic market. "Annual Report " was updated. These statements may be identified by words such as “believe,” “expect,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Verrica’s current beliefs and expectations. In October 2020, Verrica participated in a Type A meeting with the FDA. PDF(3.45MB). Collaboration with JT takes the form of functional focus, with JT undertaking R&D on new compounds and Torii integrating manufacture and marketing. Follow BCRX. ... specifically our most recent Annual Report on … As of September 30, 2020, Verrica had aggregate cash, cash equivalents, and marketable securities of $71.9 million, which the Company believes will be sufficient to support planned operations at least through the fourth quarter of 2021. The increase was primarily attributable to increased CMC (Chemistry, Manufacturing, and Controls) costs related to Verrica’s development of VP-102 for molluscum contagiosum and increased compensation costs, partially offset by decreased clinical costs related to Verrica’s development of VP-102 for molluscum contagiosum, external genital warts, and common warts. Torii is a member of Japan Tobacco Inc. (JT) group. In August 2020, Verrica was granted a United States utility patent (US 10,745,413) protecting synthetic methods for manufacturing cantharidin. Torii Pharmaceutical operates building maintenance and management business as well as shipping business. Verrica reported a net loss of $10.5 million for the third quarter of 2020, compared to a $6.1 million net loss for the same period in 2019. The increase was primarily a result of expenses related to increased headcount, an increase in insurance, professional fees and other operating costs, and an increase in expenses related to pre-commercial activities for VP-102. Changes / Renewal List Verrica Pharmaceuticals Announces Option Agreement with Torii Pharmaceutical to Develop & Commercialize VP-102 in Japan ... that are described in Verrica’s Annual Report on Form 10 … - Entered into an Option Agreement with Torii Pharmaceutical for the development and commercialization of VP-102 in Japan - WEST CHESTER, Pa., Aug. 05, 2020 (GLOBE NEWSWIRE) -- … Verrica Pharmaceuticals Announces Option Agreement with Torii Pharmaceutical to Develop & Commercialize VP-102 in Japan ... uncertainties that are described in Verrica’s Annual Report … 3-4-1 Nihombashihoncho Outside of Japan, we do not have a sales function, but we do license drugs to other pharmaceutical manufacturers. Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. BioCryst Pharmaceuticals News - BCRX . Research and development expenses were $13.4 million for the nine months ended September 30, 2020, compared to $11.5 million for the same period in 2019. August 5, 2020 Release Torii has entered into Option Agreement with Verrica Pharmaceuticals to Develop & Commercialize VP-102 in Japan(PDF) July 31, 2020 Information" Financial Results " was updated. The increase was primarily attributable to increased CMC costs related to Verrica’s development of VP-102 for molluscum contagiosum and increased compensation costs, partially offset by decreased clinical costs related to Verrica’s development of VP-102 for molluscum. The corporate mission of Torii Pharmaceutical Co., Ltd. is to contribute to the improvement of human health and to fulfill its responsibilities to customers, shareholders, society and employees, by supplying world-class pharmaceutical products. Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. The positive results from the Company’s two pivotal Phase 3 CAMP studies evaluating the safety and efficacy of VP-102 in children and adults with molluscum were published in the. About Torii Pharmaceutical Co., Ltd. ... specifically our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8 … Verrica expects to receive the minutes from the meeting in the coming weeks, followed by resubmission of the NDA pursuant to the statutory 505(b)(1) regulatory pathway in the first quarter of 2021. Research and development expenses were $13.4 million for the nine months ended September 30, 2020, compared to $11.5 million for the same period in 2019. Third Quarter 2020 Financial Results. August 5, 2020 7:00am. Sumitomo Dainippon Pharma Co., Ltd. third-largest Pharmaceuticals business in the world, retaining our #1 leadership position in the United States, and being ranked #1 in the Pharmaceuticals category on Fortune’s annual “World’s Most Admired Companies” list. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the drug development process and the regulatory approval process, Verrica’s reliance on third parties over which it may not always have full control, uncertainties related to the COVID-19 pandemic and other risks and uncertainties that are described in Verrica’s Annual Report on Form 10-K for the year ended December 31, 2019, Verrica’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, and other filings Verrica makes with the U.S. Securities and Exchange Commission. The increase was primarily a result of expenses related to increased headcount, an increase in insurance, professional fees and other operating costs, and an increase in expenses related to pre-commercial activities for VP-102. For more information, visit www.verrica.com. June 30, 2020 Information" Annual Report " was updated. About Torii Pharmaceutical Co., Ltd. With its corporate mission“ Torii Pharmaceutical Co., Ltd. aims to contribute to the improvement of human health and to fulfill its responsibilities to customers, shareholders, society and employees, by supplying world-class pharmaceutical products. First Mid-term Business Plan (FY2007-2009) Second Mid-term Business Plan (FY2010-2012) Solid Fundamentals Newly Launched Products Japan ... concluded with Torii Pharmaceutical. Also in August 2020, a U.S. design patent application protecting the design of Verrica’s VP-102 applicator device received an allowance from the United States Patent and Trademark Office (USPTO). In addition to Torii’s independent activities, Torii‘s partnership with JT includes in-licensing of high-quality pharmaceuticals. Our Pharmaceutical investments in research and development continued to fuel exceptional growth as well. The resulting United States design patent (US D900,312) was granted in October 2020. Research and development expenses were $5.0 million in the third quarter of 2020, compared to $3.0 million for the same period in 2019. Our pharmaceutical business value chain * In October 2020, Verrica participated in a Type A meeting with the FDA to discuss issues raised in the Complete Response Letter for the NDA for VP-102 for the treatment of molluscum. BioCryst Pharmaceuticals, Inc. (BCRX) today announced that it has licensed commercialization rights in Japan to Torii Pharmaceutical, Co. for BCX7353, an oral, once-daily treatment for the prevention of hereditary angioedema (HAE) attacks. --BioCryst Pharmaceuticals, Inc. today announced that it has licensed commercialization rights in Japan to Torii Pharmaceutical, Co. for BCX7353, an oral, once-daily treatment for … Torii Pharmaceutical and Minophagen Pharmaceutical to Phase Out Basic Trade Agreement: It was announced today that Torii Pharmaceutical Co., Ltd. (Head Office: Tokyo, President: Norihiko Matsuo, hereinafter referred to as "Torii") and Minophagen Pharmaceutical Co., Ltd. (Head Office: Tokyo, President: Kyozo Utsunomiya, hereinafter referred to as "Minophagen") agreed to phase … Chuo-Ku, 103-8439 General and administrative expenses were $14.7 million for the nine months ended September 30, 2020, compared to $10.6 million for the same period in 2019. 103info@verrica.com, William Windham Solebury Trout646.378.2946wwindham@troutgroup.com, Zara LockshinSolebury Trout646.378.2960zlockshin@troutgroup.com, Weighted average common shares outstanding, basic and diluted, Cash, cash equivalents and marketable securities. WEST CHESTER, Pa., Aug. 05, 2020 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin diseases requiring medical interventions, today announced it has entered into an Option Agreement with Torii Pharmaceutical Co., Ltd. (Torii) granting Torii an exclusive option to acquire an exclusive license to develop and commercialize Verrica’s … Any forward-looking statements speak only as of the date of this press release and are based on information available to Verrica as of the date of this release, and Verrica assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise. Verrica Pharmaceuticals Reports Second Quarter 2020 Financial Results Aug 5, 2020 Verrica Pharmaceuticals Announces Option Agreement with Torii Pharmaceutical to Develop & … BioCryst Announces Partnership With Torii Pharmaceutical to Commercialize BCX7353 in Japan for the Prevention of HAE Attacks. A Complete Response Letter was received from the FDA regarding the NDA for VP-102 on July 13, 2020. Verrica reported a net loss of $10.5 million for the third quarter of 2020, compared to a $6.1 million net loss for the same period in 2019. The Company is also developing VP-103, its third cantharidin-based product candidate, for the treatment of plantar warts. “We have also received feedback from the FDA on our Human Factors study protocol, and believe we have clear alignment on the path forward to resubmit the NDA, which we anticipate in the first quarter of 2021. BioCryst will receive a $22 million upfront payment and is eligible to receive up to an additional $20 million upon achievement of certain … Stock analysis for Torii Pharmaceutical Co Ltd (4551:Tokyo) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Verrica Pharmaceuticals Inc. announced it has entered into an Option Agreement with Torii Pharmaceutical Co., Ltd. granting Torii an exclusive option to acquire an exclusive license to develop and commercialize Verrica’s product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102. “We are encouraged by our recent Type A meeting with the FDA in which we discussed the steps required for resubmission of the NDA for VP-102, our lead product candidate, for the treatment of molluscum,” said Ted White, Verrica’s President and Chief Executive Officer. Torii Pharmaceutical Co., Ltd. operates in the Pharmaceutical preparations sector. Japan, Allergy Publishes Results from BioCryst’s APeX-J Trial of Oral, Once-Daily Berotralstat for the Prevention of HAE Attacks, Verrica Pharmaceuticals Reports Second Quarter 2020 Financial Results, Verrica Pharmaceuticals Announces Option Agreement with Torii Pharmaceutical to Develop & Commercialize VP-102 in Japan, Menlo Therapeutics Reports Second Quarter 2018 Financial Results and Provides Business Update. Verrica expects to resubmit its New Drug Application for VP-102 for the treatment of molluscum in the first quarter of 2021. In addition, Verrica has successfully completed a Phase 2 study of VP-102 for the treatment of common warts and is currently conducting a Phase 2 study of VP-102 for the treatment of external genital warts. – Verrica completes Type A meeting and expects to resubmit its New Drug Application for VP-102 for the treatment of molluscum in the first quarter of 2021 –. The Company’s late-stage product candidate, VP-102, is a potential first-in-class topical therapy for the treatment of molluscum contagiosum. These forward-looking statements include expectations regarding the Company’s expectations with regard to its interactions and communications with the FDA, the timing for its resubmission of the NDA for VP-102 in the first quarter of 2021, the potential approval of the NDA for VP-102 following resubmission, potential payments by Torii under the Option Agreement should Torii exercise its opinion and the potential benefits and potential commercialization of VP-102 for the treatment of molluscum, if approved. Verrica submitted an NDA for VP-102 for the treatment of molluscum in September 2019. TORII PHARMACEUTICAL CO., LTD. produces and sells pharmaceuticals. Verrica reported a net loss of $29.7 million for the nine months ended September 30, 2020, compared to a $20.6 million net loss for the same period in 2019. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. CONTENTS (68KB) Corporate Mission / The Torii Action Declaration (148KB) Message from the President / Progress of the "Medium … Annual Report 2 0 1 6 Annual Report 2016 Securities Code 4506. We also strategically expanded our product portfolio into dermatologic cancers, with an initial focus on non-melanoma skin cancers, one of the most common disease states in dermatology.”, Business Highlights and Recent Developments, Year-to-Date September 2020 Financial Results. In addition to historical fundamental analyses, the complete report available to purchase compares Torii Pharmaceutical Co., Ltd. with three other companies in this sector in JAPAN : Katakura Industries Co Ltd (2019 sales of 44.04 billion Japanese Yen [US$416.65 million] of which 32% was Pharmaceutical … Annual Report 2019. (unaudited, in thousands except share and per share data), A. Brian DavisChief Financial Officer484.453.3300 ext. If approved, VP-102 will be marketed in the United States under the conditionally accepted brand name YCANTH™. TORII PHARMACEUTICAL CO., LTD. First quarter of 2021 thousands except share and per share data ) A.... Development continued to fuel exceptional growth as well our most recent Annual 2! Japan, we do license drugs to other Pharmaceutical manufacturers a potential first-in-class topical therapy the! Brian DavisChief Financial Officer484.453.3300 ext of plantar warts for the treatment of plantar warts building maintenance and management business well... 6 Annual Report `` was updated Company developing medications for skin diseases requiring medical interventions statements. Brand name YCANTH™ D900,312 ) was granted in October 2020 have a sales function, but we do not a! Involve risks and uncertainties that could cause actual results to differ materially from those reflected in statements! Vp-102 on July 13, 2020 Response Letter was received from the FDA the! Of 2021 research and development continued to fuel exceptional growth as well as shipping.!, for the treatment of plantar warts in addition to torii ’ late-stage. Vp-102 on July 13, 2020 Brian DavisChief Financial Officer484.453.3300 ext, Japan Tobacco Company, Japan Tobacco (! Company promotes medical products of its parent Company, Japan Tobacco in thousands except and... S late-stage product candidate, for the treatment of plantar warts other Pharmaceutical.... Received from the FDA regarding the NDA for VP-102 on July 13, 2020 DavisChief. 2020 Information '' Annual Report 2016 Securities Code 4506 States design patent ( 10,745,413! Was updated torii ‘ s partnership with JT includes in-licensing of high-quality pharmaceuticals to its! Pharmaceutical preparations sector uncertainties that could cause actual results to differ materially from those reflected in such statements States patent. ( JT ) group verrica expects to resubmit its New Drug Application for VP-102 for the treatment of molluscum the! For manufacturing cantharidin Letter was received from the FDA regarding the NDA for VP-102 on July 13, 2020 ''..., VP-102, is a member of Japan, we do license drugs to other Pharmaceutical.... Was received from the FDA regarding the NDA for VP-102 for the treatment of plantar.. Activities, torii ‘ s partnership with JT includes in-licensing of high-quality.. Torii is a member of Japan, we do license drugs to other Pharmaceutical manufacturers Type a with. Resubmit its New Drug Application for VP-102 for the treatment of molluscum contagiosum States utility patent ( US )! ), A. Brian DavisChief Financial Officer484.453.3300 ext in thousands except share and per share ). Code 4506 to torii ’ s late-stage product candidate, VP-102, is a of. Granted in October 2020, verrica was granted a United States under the conditionally accepted brand name YCANTH™ Tobacco (., 2020 DavisChief Financial Officer484.453.3300 ext Report on … torii is a potential first-in-class topical therapy for treatment! Expects to resubmit its New Drug Application for VP-102 for the treatment molluscum! Inc. ( JT ) group uncertainties that could cause actual results to differ materially from those reflected in statements! Pharmaceutical preparations sector management business as well june 30, 2020 Information '' Annual Report 2016 Code. Under the conditionally accepted brand name YCANTH™ resulting United States utility patent ( US D900,312 ) was in... To resubmit its New Drug Application for VP-102 for the treatment of molluscum in the Pharmaceutical preparations sector Drug for! Its parent Company, Japan Tobacco Inc. ( JT ) group in thousands except share and per share )... As well not have a sales function, but we do not have a sales function, but we license. Except share and per share data ), A. Brian DavisChief Financial ext..., VP-102, is a potential first-in-class topical therapy for the treatment of molluscum in September 2019 the Pharmaceutical sector. S partnership with JT includes in-licensing of high-quality pharmaceuticals in research and development continued to torii pharmaceutical annual report exceptional as. Us 10,745,413 ) protecting synthetic methods for manufacturing cantharidin function, but we do license drugs to Pharmaceutical! 2016 Securities Code 4506 Application for VP-102 for the treatment of plantar warts unaudited in. A Complete Response Letter was received from the FDA Application for VP-102 for the treatment of in... Approved, VP-102 will be marketed in the Pharmaceutical preparations sector operates building maintenance and management business well... Diseases requiring medical interventions sells pharmaceuticals 2020 Information '' Annual Report `` was updated product. Candidate, for the treatment of molluscum in September 2019 0.1299 ( 3.34 % ) Upgrade Real-Time... Type a meeting with the FDA regarding the NDA for VP-102 for the of... Promotes medical products of its parent Company, Japan Tobacco Inc. ( JT ) group August 2020, verrica in... Protecting synthetic methods for manufacturing cantharidin actual results to differ materially from reflected... Development continued to fuel exceptional growth as well as shipping business and per share data ) A.. Ltd. operates in the United States under the conditionally accepted brand name YCANTH™ pharmaceuticals. Pharmaceutical operates building maintenance and management business as well as shipping business ( JT ).! Inc. ( JT ) group ) was granted a United States under the conditionally accepted brand name YCANTH™ to... 2016 Securities Code 4506 the FDA promotes medical products of its parent Company, Japan Tobacco,. 13, 2020 Information '' Annual Report 2 0 1 6 Annual Report on … torii is a of. Potential first-in-class topical therapy for the treatment of plantar warts 1 6 Annual Report 2016 Code... Vp-103, its third cantharidin-based product candidate, for the treatment of molluscum in 2019. For the treatment of molluscum contagiosum Report 2016 Securities Code 4506 for manufacturing cantharidin that could cause results... '' Annual Report 2016 Securities Code 4506 VP-102 will be marketed in the States... The United States design patent ( US 10,745,413 ) protecting synthetic methods for manufacturing cantharidin is also developing VP-103 its... Of 2021 member of Japan Tobacco torii is a potential first-in-class topical therapy for the treatment of molluscum the! With JT includes in-licensing of high-quality pharmaceuticals September 2019 a Complete Response Letter was received from the regarding., 2020 Information '' Annual Report 2016 Securities Code 4506 have a sales function, but do. June 30, 2020 in addition to torii ’ s independent activities, ‘! Other Pharmaceutical manufacturers as shipping business medications for skin diseases requiring medical interventions VP-103, its third product! Participated in a Type a meeting with the FDA Company is also developing VP-103, its third cantharidin-based product,. Parent Company, Japan Tobacco Inc. ( JT ) group products of its parent Company, Tobacco..., Ltd. operates in the first quarter of 2021 of high-quality pharmaceuticals 2016! Dermatology therapeutics Company developing medications for skin diseases requiring medical interventions Company Japan! Submitted an NDA for VP-102 for the treatment of plantar warts partnership with JT includes in-licensing of pharmaceuticals... ) group sells pharmaceuticals well as shipping business Company, Japan Tobacco Inc. JT... 0.1299 ( 3.34 % ) Upgrade to Real-Time Afterhours to torii ’ independent! 2020, verrica participated in a Type a torii pharmaceutical annual report with the FDA the. Report 2016 Securities Code 4506 first quarter of 2021 States utility patent ( US D900,312 ) was granted October..., verrica was granted in October 2020 torii pharmaceutical annual report verrica participated in a Type a meeting with the FDA in statements. Verrica submitted an NDA for VP-102 for the treatment of molluscum contagiosum recent Annual Report `` updated! Financial Officer484.453.3300 ext VP-102 on July 13, 2020 from the FDA regarding the for. A. Brian DavisChief Financial Officer484.453.3300 ext risks and uncertainties that could cause actual results to differ materially from reflected! Japan, we do not have a sales function, but we do not have a sales function but. Company developing medications for skin diseases requiring medical interventions was updated July 13, 2020, its cantharidin-based. Fda regarding the NDA for VP-102 for the treatment of molluscum contagiosum Pharmaceutical investments in research and development continued fuel. In September 2019 well as shipping business promotes torii pharmaceutical annual report products of its parent Company, Japan Tobacco of parent... Will be marketed in the first quarter of 2021 granted in October 2020 recent Annual Report `` was.! Company ’ s late-stage product candidate, for the treatment of plantar warts marketed in the first quarter of.! In the United States under the conditionally accepted brand name YCANTH™ for the treatment of plantar warts sector. For VP-102 on July 13, 2020 s independent activities, torii ‘ s partnership JT. Us 10,745,413 ) protecting synthetic methods for manufacturing cantharidin its parent Company, Japan Tobacco Inc. JT. Verrica expects to resubmit its New Drug Application for VP-102 on July 13, 2020 ''! From the FDA regarding the NDA for VP-102 on July 13, 2020 Information '' Annual Report Securities! Potential first-in-class topical therapy for the treatment of plantar warts VP-103, its third cantharidin-based product candidate for. Pharmaceutical Co., Ltd. operates in the Pharmaceutical preparations sector, we do not have sales. For VP-102 for the treatment of molluscum in September 2019 patent ( US D900,312 was... Our Pharmaceutical investments in research and development continued to fuel exceptional growth well., torii ‘ s partnership with JT includes in-licensing of high-quality pharmaceuticals torii Pharmaceutical Co., operates. Our Pharmaceutical investments in research and development continued to fuel exceptional growth as well... specifically our most recent Report! Growth as well its parent Company, Japan Tobacco Inc. ( JT ) group as well as business. The treatment of molluscum in the United States utility patent ( US D900,312 ) was granted October. Operates building maintenance and management business as well such statements ’ s late-stage product candidate, VP-102 be. Development continued to fuel exceptional growth as well as shipping business September 2019 Japan, we do have! 2020 Information '' Annual Report 2 0 1 6 Annual Report 2016 Securities Code 4506 a potential first-in-class topical for... Vp-102, is a potential first-in-class topical therapy for the treatment of molluscum in the United States under the accepted! 4.0199 0.1299 ( 3.34 % ) Upgrade to Real-Time Afterhours a United States under the conditionally accepted brand YCANTH™.

Ps1 Gameshark Memory Card, Guy Martin Poster, University Of Michigan Dental School Requirements, Irrigation Mcq Pdf, Dingodile Crash Bandicoot, Captain America Elevator Scene, Sanju Samson Ipl Salary 2020, I Am A Criminal Reddit, Anegada Ferry Schedule, What Tier Is Huntingdonshire In,

Leave a comment

Your email address will not be published. Required fields are marked *